OptimizeRx Q4 net income $5.0M, record adj EBITDA $12.0M; guides FY2026 rev $109-114M

OptimizeRx Corp

Q4 revenue $32.2M (flat YoY); FY2025 revenue $109.4M (+19% YoY).
Q4 GAAP net income $5.0M ($0.26/diluted share) vs net loss $0.1M in Q4 2024.
Q4 adjusted EBITDA record $12.0M; FY2025 adj EBITDA $24.3M.
FY2026 guidance: revenue $109-114M, adjusted EBITDA $21-25M.
Board authorizes $10M share repurchase program effective Mar 12, 2026 through Mar 15, 2027.

item 1.01 item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

OptimizeRx Corp reported fiscal year 2026 results: revenue $109 million and $114 million. Guidance initiated.

Period: fiscal year 2026
Revenue: $109 million and $114 million
Guidance: initiated
Result: guidance update

Exact text from the filing

The Company is also updating its fiscal year 2026 guidance at this time and is expecting revenue to be between $109 million and $114 million with Adjusted EBITDA to be between $21 million and $25 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

OptimizeRx Corp reported fourth quarter and full year ended December 31, 2025 results: revenue Q4 revenue of $32.2 million; Full year revenue for 2025 came in at $109.4 million, net income Q4 net income ... $5.0 million; GAAP net income for the full year of 2025 totaled $5.1 million, EPS $0.26 per diluted share (Q4); $0.27 per diluted share (full year 2025). Guidance initiated.

Period: fourth quarter and full year ended December 31, 2025
Revenue: Q4 revenue of $32.2 million; Full year revenue for 2025 came in at $109.4 million
Net income: Q4 net income ... $5.0 million; GAAP net income for the full year of 2025 totaled $5.1 million
EPS: $0.26 per diluted share (Q4); $0.27 per diluted share (full year 2025)
Guidance: initiated
Result: reported results

Exact text from the filing

On March 5, 2026 , the Company issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025, providing key performance indicators, updated 2026 guidance and announcing a new $10 million share repurchase program.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

OptimizeRx Corp amended Amendment No. 4 (effective 2026-03-02).

Action: amendment
Agreement: credit facility
Effective: 2026-03-02

Exact text from the filing

On March 2, 2026, OptimizeRx Corporation (the “Company”) entered into Amendment No. 4 to the Financing Agreement (the “Amendment No. 4”).

View on SEC.gov

Browse all earnings releases →

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001448431-26-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.